Treatment Information

Back

Brain – Glioblastoma Multiforme treatment details. Biologic therapy.

Hygeia Hospital, Athens, Greece.

Survival: monthsCountry:Greece
Toxiciy Grade:3City/State/Province:Athens
Treatments:Biologic therapyHospital:Hygeia Hospital
Drugs:Journal:Link
Date:Oct 2009

Description:

Patients: This phase 2 study involved 20 patients with glioblastoma multiforme. Three of these patients had a mix of glioblastoma and astrocytoma. There were 14 men and six women in this study.

Treatment: Patients were treated with the biological therapy imatinib.

Toxicity: Grade 3 respiratory toxicity was reported in two patients, urinary tract infection in one, and fatigue/anemia in two patients. Grade 3 central nervous system toxicities were seizure, dysarthria, and epidural hematoma (one of each). One diabetic patient also had poorly controlled blood sugar.

Results: The median overall survival was 6.2 months.

Support: This study was supported by Novartis Pharmaceuticals, which markets imatinib as Gleevec.

Correspondence: Dr. Evangelia Razis



Back